Table 9.

Examples of sugar-functionalized nanoparticles for targeted drug delivery.

Carrier	Drug	Sugar	Target	Tumor Model	Ref.
PLGA nanoparticle		Hyaluronic acid	CD44, LYVE-1 RHAMM	Different cell models (in vitro)	[188]
Liposome	Oxaliplatin	Hyaluronic acid	CD44, LYVE-1 RHAMM	Colon cancer (in vitro and in vivo)	[189]
Chitosan nanoparticle	Doxorubicin	Hyaluronic acid	CD44, LYVE-1 RHAMM	Breast cancer (in vitro)	[190]
Chitosan nanoparticle	Doxorubicin + miR3a	Hyaluronic acid	CD44, LYVE-1 RHAMM	Breast cancer (in vitro and in vivo)	[191]
Albumin nanoparticle	Doxorubicin	Hyaluronic acid	CD44, LYVE-1 RHAMM	Breast cancer (in vitro)	[192]
Albumin-TPGS nanoparticle	Paclitaxel	Chondroitin sulfate	CD44	Breast cancer (in vitro and in vivo)	[193]
PEI-PLGA nanoparticle	Olaparib	Hyaluronic acid	CD44, LYVE-1 RHAMM	Breast cancer (in vitro and in vivo)	[194]
TPGS-prodrug nanoparticle	Dasatinib	Hyaluronic acid	CD44, LYVE-1 RHAMM	Epithelial tumor cells + healthy animals (in vitro and in vivo)	[195]
mPEG copolymer nanoparticle	Cantharidin	Hyaluronic acid	CD44, LYVE-1 RHAMM	Liver cancer (in vitro and in vivo)	[196]
Prodrug-PLGA nanoparticle	Cabazitaxel + orlistat	Hyaluronic acid	CD44, LYVE-1 RHAMM	Prostate cancer (in vitro and in vivo)	[197]
Silk fibroin nanoparticle	Curcumin + 5-FU	Hyaluronic acid	CD44, LYVE-1 RHAMM	Breast cancer (in vitro and in vivo)	[198]
Poloxamer 407 nanoparticle	Resveratrol + tamoxifen	Hyaluronic acid	CD44, LYVE-1 RHAMM	Breast cancer cells + healthy animals (in vitro and in vivo)	[199]
Polymersome	Doxorubicin + captothecin + α-FOXM1	Hyaluronic acid	CD44, LYVE-1 RHAMM	Lung cancer (in vitro and in vivo)	[200]
Fucoidan nanoparticle	S63845 + venetoclax	Fucoidan	P-selectin	B-cell malignancy (in vitro and in vivo)	[201]
Metal organic framework	Talazoparib + temozolomide	Fucoidan	P-selectin	Colon cancer (in vitro and in vivo)	[202,203]
Ginger lipid nanoparticle	Doxorubicin	Fucoidan	P-selectin	Colon cancer (in vitro and in vivo)	[204]